Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim…
– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly…
– New blinded preliminary BRTX-100 data described this past Saturday at prestigious “2025 Winners in Industry Innovations in MSK Health”…
ROSEMONT, Ill., Feb. 7, 2025 /PRNewswire/ -- Nicolas S. Piuzzi, MD, was recognized as the 2025 Kappa Delta Young Investigator Award…
MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…
MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…
TORRINGTON, Conn., Jan. 29, 2025 /PRNewswire/ -- Therap Services, the premier provider of HIPAA-compliant electronic documentation solutions for organizations and…
MINNEAPOLIS, Jan. 29, 2025 /PRNewswire/ -- Joshin, a leading provider of neurodivergent and disability support services, and Integrate Autism Employment…
HANOVER, Mass., Jan. 29, 2025 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to…